Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028182) CANCER TREATMENT USING ANTIBODIES THAT BIND HUMAN CD134 (OX40) RECEPTOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028182 International Application No.: PCT/US2018/044882
Publication Date: 07.02.2019 International Filing Date: 01.08.2018
IPC:
A61K 39/395 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
REMD BIOTHERAPEUTICS, INC. [US/US]; 4010 Adolfo Road Camarillo, CA 93012, US
Inventors:
CALZONE, Frank, J.; US
YAN, Hai; US
ZHANG, John; US
Agent:
CRANDALL, Craig, A.; US
Priority Data:
62/539,94601.08.2017US
Title (EN) CANCER TREATMENT USING ANTIBODIES THAT BIND HUMAN CD134 (OX40) RECEPTOR
(FR) TRAITEMENT DU CANCER À L'AIDE D'ANTICORPS SE LIANT AU RÉCEPTEUR CD134 HUMAIN (OX40)
Abstract:
(EN) This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting OX40 expressed on injured tissues associated with multiple diseases. These OX40 antibodies, or antigen-binding fragments thereof, have a high affinity for OX40 and function as OX40 agonists or as OX40/OX40L antagonists. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.
(FR) L'invention concerne, entre autres, des anticorps ou des fragments de liaison aux antigènes de ceux-ci, ciblant OX40 exprimé sur des tissus lésés en lien avec plusieurs maladies. Ces anticorps OX40 ou leurs fragments de liaison à l'antigène ont une affinité élevée vis-à-vis d’OX40 et fonctionnent en tant qu'agonistes d’OX40 ou en tant qu'antagonistes OX40/OX40L. Les anticorps et les fragments de liaison à l'antigène sont utiles pour le traitement de maladies, d'infections et d'autres pathologies humaines.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)